Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.44 |
| ▸ | ESR1 | P03372 | 10/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577609 | 0.92 | RORC (0.43) | RORCPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7458622 | 0.92 | RORC (0.45) | RORCPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2581362 | 0.89 | KEAP1 (0.47) | RORCESR1MCL1BCL2L1 | |
| SCHEMBL13673923 | 0.86 | RORC (0.41) | RORCPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2581276 | 0.84 | KEAP1 (0.44) | RORCPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5996194 | 0.83 | CYP2C8 (0.40) | RORCESR1PSEN1PSEN2APH1B | |
| SCHEMBL2578817 | 0.82 | MMP2 (0.47) | RORC | |
| SCHEMBL6871955 | 0.80 | ALDH1A1 (0.41) | RORC | |
| SCHEMBL5026552 | 0.80 | RORC (0.36) | RORCPSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL5027237 | 0.80 | RORC (0.36) | RORCPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-7115618-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6846954-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | disclosed |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-03-04 | — | — | US | disclosed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
| US-6060476-A | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | RORC 3583/4885ESR1 1312/4885PSEN1 192/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | RORC 3253/4885ESR1 1279/4885PSEN1 160/4885 |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PREP, ANPEP | RORC 3701/4885ESR1 1431/4885PSEN1 233/4885 |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | RORC 3583/4885ESR1 1312/4885PSEN1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.